During the past decade, Praxis für Urologie conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Praxis für Urologie" are "Advanced or Metastatic Renal Cell Carcinoma" (1 trials), "Prostate Cancer" (1 trials) and "Renal Cell Carcinoma" (1 trials). Many other conditions were trialed in "Praxis für Urologie" in a lesser frequency.

Most popular intervention types in "Praxis für Urologie" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Pazopanib+Sorafenib" (1 trials), "Sorafenib+Pazopanib" (1 trials) and "Triptorelin Pamoate (Pamorelin® LA 11.25 mg)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Praxis für Urologie" are 2 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Praxis für Urologie". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Praxis für Urologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Praxis für Urologie, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".